ClinicalTrials.gg
CompletedNCT02925117Updated Jul 16, 2020Results posted

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of Upadacitinib and Placebo in Atopic Dermatitis, sponsored by AbbVie. Completed at 34 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
11th of 17
167 · median 272
Started
2016
the only one that year
Phase 2
2 of 17
1 open now
Registered
1st of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 11th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).

Read the detailed description

The study was to include a 16-week double-blind treatment period (Period 1) and a 72-week double-blind treatment period (Period 2) for a total of 88 weeks of treatment. Participants who met eligibility criteria were to be randomized in a 1:1:1:1 ratio to one of the four treatment groups. Participants who completed Period 1 were re-randomized at Week 16 into a 72-week double-blind, placebo-controlled treatment period (Period 2) in a 1:1 ratio:

  • Group 1: Upadacitinib 7.5 mg once daily (QD) (Day 1 to Week 16) → upadacitinib 7.5 mg QD or placebo (Week 16 - and thereafter)
  • Group 2: Upadacitinib 15 mg QD (Day 1 to Week 16) → upadacitinib 15 mg QD or placebo (Week 16 and thereafter)
  • Group 3: Upadacitinib 30 mg QD (Day 1 to Week 16) → upadacitinib 30 mg QD or placebo (Week 16 - and thereafter)
  • Group 4: Matching placebo (Day 1 to Week 16) → upadacitinib 30 mg QD or placebo (Week 16 and thereafter)

In Period 1, discontinuation from study drug was mandatory for any participant with an Eczema Area and Severity Index (EASI) score worsening of 25% or more compared with their Baseline EASI score at any 2 consecutive scheduled study visits from Week 4 to Week 12.

In Period 2, blinded rescue therapy with upadacitinib 30 mg QD was provided after the first instance of a \< EASI 50 response starting at the Week 20 visit (4 weeks after re-randomization into Period 2) for the remainder of the study.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • ABT-494
  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the Hanifin and Rajka criteria) and onset of symptoms at least 1 year prior to Baseline.
  • Moderate to severe atopic dermatitis defined by an Eczema Area and Severity Index (EASI) ≥ 16, body surface area (BSA) ≥ 10% and an Investigators Global Assessment (IGA) score ≥ 3 at the Baseline visit.
  • Documented history (within 1 year prior to the screening visit) of inadequate response to treatment with topical (TCS), or topical calcineurin inhibitors (TCI), or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks).
  • Twice daily use of an additive-free, bland emollient for at least 7 days prior to Baseline.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any systemic or topical Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, ruxolitinib, and filgotinib).
  • Treatment with topical (TCS), topical calcineurin inhibitors (TCI), prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin within 10 days prior to the Baseline visit.
  • Prior exposure to dupilumab or exposure to systemic therapies for AD including corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE4)-inhibitors and mycophenolate mofetil within 4 weeks prior to Baseline.
  • Prior exposure to any systemic treatment within 30 days or 5 half-lives (whichever is longer) of the Baseline visit or is currently enrolled in another clinical study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Upadacitinib 7.5 mg

    Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Upadacitinib 15 mg

    Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.

    Drug: Upadacitinib · Drug: Placebo

  • Experimental
    Upadacitinib 30 mg

    Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.

    Drug: Upadacitinib · Drug: Placebo

Interventions

  • Tablet for oral use

    Also known as: RINVOQ™, ABT-494

  • DrugPlacebo

    Tablet

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 16

    EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Week 16

  2. Percentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 16

    The Investigator's Global Assessment for Atopic Dermatitis (IGA) was scored on the following scale: * 0: Clear (No inflammatory signs of atopic dermatitis) * 1: Almost Clear (Just perceptible erythema and just perceptible papulation/infiltration) * 2: Mild (Mild erythema and mild papulation/infiltration) * 3: Moderate (Moderate erythema and moderate papulation/infiltration) * 4: Severe (Severe erythema and severe papulation/infiltration with or without oozing/crusting) The percentage of participants with a score of 0 or 1 at Week 16 is reported.

    Time frame: Week 16

  3. Percent Change From Baseline to Weeks 2, 8, and 16 in Pruritus Numerical Rating Scale (NRS)

    Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percent change from Baseline at each week was calculated from a rolling weekly average.

    Time frame: Baseline and Weeks 2, 8, and 16

  4. Percent Change From Baseline in EASI Score at Week 8

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 8

  5. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Weeks 8 and 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Weeks 8 and 16

  6. Percentage of Participants Who Achieved an EASI 75 Response at Week 8

    EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 8 were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Week 8

  7. Percentage of Participants Who Achieved an EASI 50 Response at Weeks 8 and 16

    EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 50 response is defined as participants with at least a 50% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Weeks 8 and 16

  8. Percentage of Participants Who Achieved an EASI 90 Response at Weeks 8 and 16

    EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 90 response is defined as participants with at least a 90% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Weeks 8 and 16

  9. Percentage of Participants Who Achieved a SCORAD 50 Response at Weeks 8 and 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 50 response is defined as participants with at least a 50% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Weeks 8 and 16

  10. Percentage of Participants Who Achieved a SCORAD 75 Response at Weeks 8 and 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as participants with at least a 75% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Weeks 8 and 16

  11. Percentage of Participants Who Achieved a SCORAD 90 Response at Weeks 8 and 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as participants with at least a 90% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Weeks 8 and 16

  12. Percent Change From Re-randomization (Week 16) in EASI Score in Period 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Re-randomization (Week 16) and Weeks 20, 24, 32, 40, 52, 64, 76, and 88

  13. Time to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16

    Time to loss of EASI 50 response in Period 2 relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16. Time to loss of EASI 50 response was measured from Week 16 to the date of the first assessment in Period 2 where a participant's EASI score was higher than 50% of their Baseline score. Participants with no loss of response were censored at their last treatment visit or the start of rescue treatment, whichever occurred first.

    Time frame: From re-randomization at Week 16 until Week 88

  14. Percentage of Participants With an EASI 75 Response in Period 2 in Participants Who Were Re-randomized as EASI 75 Non-responders at Week 16

    EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) in EASI score relative to the Baseline value, and was analyzed in participants who were re-randomized at Week 16 and were EASI 75 non-responders at Week 16.

    Time frame: Weeks 20, 24, 32, 40, 52, 64, 76, and 88

  15. Percentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) of "0" or "1" at Weeks 8 and 16

    The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A score of 0 or 1 means that the disease has no effect at all. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.

    Time frame: Weeks 8 and 16

  16. Change From Baseline in DLQI at Weeks 8 and 16

    The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A negative change from Baseline indicates improvement. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.

    Time frame: Baseline and Weeks 8 and 16

  17. Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16

    Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. Last observation carried forward imputation was used.

    Time frame: Baseline and Week 16

  18. Percentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 16

    Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percentage of participants with reduction of ≥ 4 points from Baseline in pruritus NRS was assessed in participants with a baseline pruritus NRS of ≥ 4. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).

    Time frame: Baseline and Week 16

07

Results

Posted Jul 16, 2020

Participant flow

Participants were enrolled at 36 sites in 8 countries (Australia, Canada, Finland, Germany, Japan, Netherlands, Spain, and the United States \[US\]). The study included a 16-week double-blind treatment period (Period 1) followed by a a 72-week double-blind treatment period (Period 2) for a total of 88 weeks of treatment.

Period 1 (Weeks 0 - 16)
Participant flow — Period 1 (Weeks 0 - 16)
MilestonePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgPlacebo / PlaceboPlacebo / Upadacitinib 30 mgUpadacitinib 7.5 mg / PlaceboUpadacitinib 7.5 mg / Upadacitinib 7.5 mgUpadacitinib 15 mg / PlaceboUpadacitinib 15 mg / Upadacitinib 15 mgUpadacitinib 30 mg / PlaceboUpadacitinib 30 mg / Upadacitinib 30 mg
Started4142424200000000
Received treatment4042424200000000
Completed2331373900000000
Not completed18115300000000
Withdrew: Adverse event131200000000
Withdrew: Withdrawal by subject1033000000000
Withdrew: Lost to follow-up210000000000
Withdrew: Other541100000000
Period 2 (Weeks 16 - 88)
Participant flow — Period 2 (Weeks 16 - 88)
MilestonePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgPlacebo / PlaceboPlacebo / Upadacitinib 30 mgUpadacitinib 7.5 mg / PlaceboUpadacitinib 7.5 mg / Upadacitinib 7.5 mgUpadacitinib 15 mg / PlaceboUpadacitinib 15 mg / Upadacitinib 15 mgUpadacitinib 30 mg / PlaceboUpadacitinib 30 mg / Upadacitinib 30 mg
Started00001010151619181919
Rescued to upadacitinib 30 mg00008113121712144
Completed00008591113121114
Not completed000025656685
Withdrew: Adverse event000001000032
Withdrew: Withdrawal by subject000001432222
Withdrew: Lost to follow-up000012111001
Withdrew: Other000011113430

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
percent changePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16-23.0 ± 6.42-39.4 ± 6.24-61.7 ± 6.12-74.4 ± 6.13
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = < 0.001 · Least squares (ls) mean difference: -51.4 · 95% CI -66.5 to -36.3Analysis of covariance (ANCOVA) with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -38.7 · 95% CI -53.7 to -23.6Analysis of covariance (ANCOVA) with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = 0.032 · Ls mean difference: -16.4 · 95% CI -31.4 to -1.4Analysis of covariance (ANCOVA) with stratum (geographic region), baseline value, and treatment in the model.
SecondaryPercentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 16

EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Who Achieved a 75% Reduction in EASI Score (EASI 75) at Week 169.828.652.469.0
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted difference: 58.7 · 95% CI 42.5 to 74.8Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 42.5 · 95% CI 25.5 to 59.6Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.022 · Adjusted difference: 18.7 · 95% CI 2.7 to 34.7Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
SecondaryPercentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 16

The Investigator's Global Assessment for Atopic Dermatitis (IGA) was scored on the following scale: * 0: Clear (No inflammatory signs of atopic dermatitis) * 1: Almost Clear (Just perceptible erythema and just perceptible papulation/infiltration) * 2: Mild (Mild erythema and mild papulation/infiltration) * 3: Moderate (Moderate erythema and moderate papulation/infiltration) * 4: Severe (Severe erythema and severe papulation/infiltration with or without oozing/crusting) The percentage of participants with a score of 0 or 1 at Week 16 is reported.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving an Investigator Global Assessment (IGA) of "0" or "1" at Week 162.414.331.050.0
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 46.9 · 95% CI 31.1 to 62.7Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 28.6 · 95% CI 13.8 to 43.4Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.044 · Adjusted difference: 11.9 · 95% CI 0.3 to 23.5Cochran-Mantel-Haenszel test, adjusted for stratum (geographic region).
SecondaryPercent Change From Baseline to Weeks 2, 8, and 16 in Pruritus Numerical Rating Scale (NRS)

Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percent change from Baseline at each week was calculated from a rolling weekly average.

Time frame:
Baseline and Weeks 2, 8, and 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Weeks 2, 8, and 16 in Pruritus Numerical Rating Scale (NRS)
percent changePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 21.7 ± 5.59-29.3 ± 5.45-46.0 ± 5.44-57.6 ± 5.24
Week 8-6.7 ± 7.51-35.5 ± 7.28-45.1 ± 7.32-73.1 ± 7.05
Week 16-9.7 ± 8.30-39.6 ± 8.04-48.0 ± 8.08-68.9 ± 7.79
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -59.3 · 95% CI -72.3 to -46.3ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -47.7 · 95% CI -61.1 to -34.3ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = <0.001 · Ls mean difference: -31.1 · 95% CI -44.3 to -17.8ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -66.4 · 95% CI -83.9 to -48.9ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -38.4 · 95% CI -56.4 to -20.4ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = 0.002 · Ls mean difference: -28.9 · 95% CI -46.6 to -11.2ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -59.2 · 95% CI -78.6 to -39.9ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -38.3 · 95% CI -58.3 to -18.4ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = 0.003 · Ls mean difference: -29.9 · 95% CI -49.4 to -10.3ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
SecondaryPercent Change From Baseline in EASI Score at Week 8

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · percent change
Percent Change From Baseline in EASI Score at Week 8
percent changePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percent Change From Baseline in EASI Score at Week 8-17.5 ± 6.27-43.7 ± 6.09-65.4 ± 5.97-82.8 ± 5.98
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -65.3 · 95% CI -80.0 to -50.5ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -47.9 · 95% CI -62.6 to -33.3ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = <0.001 · Ls mean difference: -26.2 · 95% CI -40.8 to -11.5ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Weeks 8 and 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Weeks 8 and 16
percent changePlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 8-7.0 ± 5.84-35.4 ± 5.53-44.1 ± 5.69-65.3 ± 5.52
Week 16-12.4 ± 5.97-32.5 ± 5.66-46.9 ± 5.82-60.4 ± 5.65
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -58.3 · 95% CI -71.7 to -44.9ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -37.1 · 95% CI -50.8 to -23.4ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = <0.001 · Ls mean difference: -28.4 · 95% CI -41.9 to -15.0ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -48.0 · 95% CI -61.7 to -34.3ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -34.5 · 95% CI -48.5 to -20.5ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = 0.004 · Ls mean difference: -20.2 · 95% CI -33.9 to -6.4ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
SecondaryPercentage of Participants Who Achieved an EASI 75 Response at Week 8

EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as participants with at least a 75% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at Week 8 were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 75 Response at Week 8
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Who Achieved an EASI 75 Response at Week 87.331.052.481.0
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 72.7 · 95% CI 58.3 to 87.1Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 44.9 · 95% CI 27.9 to 61.9Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.004 · Adjusted difference: 23.4 · 95% CI 7.5 to 39.4Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercentage of Participants Who Achieved an EASI 50 Response at Weeks 8 and 16

EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 50 response is defined as participants with at least a 50% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 50 Response at Weeks 8 and 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 822.054.871.492.9
Week 1622.050.071.483.3
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 70.7 · 95% CI 56.2 to 85.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 49.0 · 95% CI 30.8 to 67.3Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 32.8 · 95% CI 13.4 to 52.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 60.6 · 95% CI 45.3 to 75.9Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 48.6 · 95% CI 31.3 to 65.9Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.003 · Adjusted difference: 28.2 · 95% CI 9.8 to 46.6Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercentage of Participants Who Achieved an EASI 90 Response at Weeks 8 and 16

EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 90 response is defined as participants with at least a 90% reduction (improvement) in EASI score relative to the Baseline value. Participants with missing values at each time point were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an EASI 90 Response at Weeks 8 and 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 80.09.526.245.2
Week 162.414.326.250.0
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 43.8 · 95% CI 29.1 to 58.5Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 26.1 · 95% CI 12.6 to 39.6Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.051 · Adjusted difference: 9.4 · 95% CI -0.0 to 18.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 46.9 · 95% CI 31.3 to 62.4Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted difference: 23.8 · 95% CI 9.6 to 38.1Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.049 · Adjusted difference: 11.8 · 95% CI 0.1 to 23.6Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercentage of Participants Who Achieved a SCORAD 50 Response at Weeks 8 and 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 50 response is defined as participants with at least a 50% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 50 Response at Weeks 8 and 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 87.333.342.976.2
Week 167.328.642.961.9
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 68.4 · 95% CI 54.0 to 82.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 35.3 · 95% CI 18.5 to 52.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted difference: 25.7 · 95% CI 9.6 to 41.7Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 54.5 · 95% CI 39.0 to 69.9Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 35.8 · 95% CI 19.1 to 52.5Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted difference: 21.2 · 95% CI 5.7 to 36.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercentage of Participants Who Achieved a SCORAD 75 Response at Weeks 8 and 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 75 response is defined as participants with at least a 75% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 75 Response at Weeks 8 and 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 80.09.59.531.0
Week 162.44.821.440.5
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 30.4 · 95% CI 16.2 to 44.6Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.052 · Adjusted difference: 9.4 · 95% CI -0.1 to 18.9Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.048 · Adjusted difference: 9.3 · 95% CI 0.1 to 18.5Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 37.7 · 95% CI 22.2 to 53.3Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted difference: 19.0 · 95% CI 5.6 to 32.5Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.581 · Adjusted difference: 2.4 · 95% CI -6.0 to 10.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercentage of Participants Who Achieved a SCORAD 90 Response at Weeks 8 and 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A SCORAD 90 response is defined as participants with at least a 90% reduction (improvement) in SCORAD score relative to the Baseline value. Participants with missing values were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a SCORAD 90 Response at Weeks 8 and 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Week 80.04.82.414.3
Week 160.02.49.523.8
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = 0.012 · Adjusted difference: 14.2 · 95% CI 3.2 to 25.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.428 · Adjusted difference: 2.3 · 95% CI -3.4 to 8.0Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.206 · Adjusted difference: 4.6 · 95% CI -2.5 to 11.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 23.3 · 95% CI 10.4 to 36.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = 0.048 · Adjusted difference: 9.4 · 95% CI 0.1 to 18.8Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.426 · Adjusted difference: 2.4 · 95% CI -3.4 to 8.1Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
SecondaryPercent Change From Re-randomization (Week 16) in EASI Score in Period 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Re-randomization (Week 16) and Weeks 20, 24, 32, 40, 52, 64, 76, and 88
Reported as:
Least squares mean · percent change
Percent Change From Re-randomization (Week 16) in EASI Score in Period 2
percent changePlacebo / PlaceboPlacebo / Upadacitinib 30 mgUpadacitinib 7.5 mg / PlaceboUpadacitinib 7.5 mg / Upadacitinib 7.5 mgUpadacitinib 15 mg / PlaceboUpadacitinib 15 mg / Upadacitinib 15 mgUpadacitinib 30 mg / PlaceboUpadacitinib 30 mg / Upadacitinib 30 mg
Week 2050.7 ± 33.5011.8 ± 30.59186.0 ± 46.5379.1 ± 48.42582.3 ± 172.1965.7 ± 178.24791.5 ± 262.34-73.8 ± 215.54
Week 2413.5 ± 17.13-67.5 ± 15.64189.6 ± 44.1759.0 ± 45.97607.3 ± 169.4972.6 ± 175.44898.5 ± 248.78-69.6 ± 200.01
Week 32-2.3 ± 15.15-83.1 ± 13.83181.5 ± 44.7463.5 ± 46.56613.3 ± 169.63151.7 ± 175.59771.5 ± 252.90-28.8 ± 210.78
Week 40-31.2 ± 18.16-92.0 ± 16.58200.9 ± 41.5877.6 ± 43.27608.8 ± 169.95154.1 ± 175.92778.9 ± 344.45140.6 ± 293.17
Week 52-29.8 ± 17.74-90.1 ± 16.20189.1 ± 43.6574.4 ± 45.42613.8 ± 166.85104.1 ± 164.05799.5 ± 254.30-13.3 ± 216.44
Week 64-35.8 ± 17.34-91.4 ± 15.83179.9 ± 44.9171.8 ± 46.74614.6 ± 166.57104.1 ± 163.78802.1 ± 278.7663.6 ± 237.26
Week 76-37.3 ± 19.09-90.3 ± 17.43201.4 ± 41.8977.7 ± 43.60614.0 ± 168.03130.2 ± 169.29787.8 ± 262.8924.4 ± 219.11
Week 88-37.7 ± 19.18-84.6 ± 17.51170.7 ± 46.8769.1 ± 48.78617.5 ± 165.8499.3 ± 163.06769.7 ± 265.6439.0 ± 226.10
SecondaryTime to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16

Time to loss of EASI 50 response in Period 2 relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16. Time to loss of EASI 50 response was measured from Week 16 to the date of the first assessment in Period 2 where a participant's EASI score was higher than 50% of their Baseline score. Participants with no loss of response were censored at their last treatment visit or the start of rescue treatment, whichever occurred first.

Time frame:
From re-randomization at Week 16 until Week 88
Reported as:
Median · days
Time to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16
daysPlacebo / PlaceboPlacebo / Upadacitinib 30 mgUpadacitinib 7.5 mg / PlaceboUpadacitinib 7.5 mg / Upadacitinib 7.5 mgUpadacitinib 15 mg / PlaceboUpadacitinib 15 mg / Upadacitinib 15 mgUpadacitinib 30 mg / PlaceboUpadacitinib 30 mg / Upadacitinib 30 mg
Time to Loss of EASI 50 Response Relative to Baseline Among Participants Re-randomized as EASI 75 Responders at Week 16NA (NA to NA)NA (NA to NA)29 (27 to NA)NA (29 to NA)30 (17 to 55)114 (29 to NA)28 (25 to 36)NA (NA to NA)
SecondaryPercentage of Participants With an EASI 75 Response in Period 2 in Participants Who Were Re-randomized as EASI 75 Non-responders at Week 16

EASI is a tool to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the percentage of skin affected, and the severity of eczema (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness, thickness, scratching, and lichenification are assessed. The EASI score is the sum of the scores for each region and ranges from 0 to 72, where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) in EASI score relative to the Baseline value, and was analyzed in participants who were re-randomized at Week 16 and were EASI 75 non-responders at Week 16.

Time frame:
Weeks 20, 24, 32, 40, 52, 64, 76, and 88
Reported as:
Number · percentage of participants
Percentage of Participants With an EASI 75 Response in Period 2 in Participants Who Were Re-randomized as EASI 75 Non-responders at Week 16
percentage of participantsPlacebo / PlaceboPlacebo / Upadacitinib 30 mgUpadacitinib 7.5 mg / PlaceboUpadacitinib 7.5 mg / Upadacitinib 7.5 mgUpadacitinib 15 mg / PlaceboUpadacitinib 15 mg / Upadacitinib 15 mgUpadacitinib 30 mg / PlaceboUpadacitinib 30 mg / Upadacitinib 30 mg
Week 2011.112.509.1012.520.025.0
Week 2410085.7—33.30033.333.3
Week 32100100—0050.050.050.0
Week 4010066.7——0100050.0
Week 5210066.7——0100—50.0
Week 6410080.0——0100—100
Week 76100100——0100—100
Week 88100100——0100—100
SecondaryPercentage of Participants Who Achieved a Dermatology Life Quality Index (DLQI) of "0" or "1" at Weeks 8 and 16

The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A score of 0 or 1 means that the disease has no effect at all. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.

Time frame:
Weeks 8 and 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in DLQI at Weeks 8 and 16

The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week in the following 6 aspects: symptoms and feelings, daily activities, leisure, work or school activities, personal relationships and treatment related feelings. Participants answer the 10 questions on a scale from 0 (not at all) to 3 (very much). The DLQI is calculated by summing the scores of the 10 questions, resulting in a maximum of 30 and a minimum of 0 with higher scores indicating more impaired quality of life. A negative change from Baseline indicates improvement. Dermatology Life Quality Index outcomes were defined but are not reported because of an error in the programming of the electronic device used to administer the questionnaire that precluded determination of these outcomes.

Time frame:
Baseline and Weeks 8 and 16

No measurements were reported for this outcome.

SecondaryChange From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16

Body surface area (BSA) affected by atopic dermatitis was assessed by the physician and is expressed as a percentage of the total BSA. For purposes of the estimation, the total surface of the participant's palm plus five digits was assumed to be approximately equivalent to 1% BSA. Last observation carried forward imputation was used.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16
percentage of body surface areaPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Percentage of Body Surface Area (BSA) Affected by Atopic Dermatitis at Week 16-4.1 ± 3.58-11.7 ± 3.48-27.1 ± 3.43-30.7 ± 3.43
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · ANCOVA · p = <0.001 · Ls mean difference: -26.5 · 95% CI -34.9 to -18.1ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 15 mg · ANCOVA · p = <0.001 · Ls mean difference: -23.0 · 95% CI -31.4 to -14.6ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
  • Placebo vs Upadacitinib 7.5 mg · ANCOVA · p = 0.075 · Ls mean difference: -7.6 · 95% CI -16.0 to 0.8ANCOVA with stratum (geographic region), baseline value, and treatment in the model.
SecondaryPercentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 16

Participants were asked to rate pruritus (itch) in the past 24 hours on a daily basis using a scale from 0 to 10, with 0 being no itch and 10 being the worst imaginable itch. The percentage of participants with reduction of ≥ 4 points from Baseline in pruritus NRS was assessed in participants with a baseline pruritus NRS of ≥ 4. Participants with missing values at Week 16 were counted as non-responders in this analysis (non-responder imputation).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 16
percentage of participantsPlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With Reduction of ≥ 4 Points From Baseline in Pruritus NRS at Week 165.724.359.452.8
Statistical analysis
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 47.4 · 95% CI 29.6 to 65.2Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted difference: 53.4 · 95% CI 35.5 to 71.3Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).
  • Placebo vs Upadacitinib 7.5 mg · Cochran-Mantel-Haenszel · p = 0.021 · Adjusted difference: 18.6 · 95% CI 2.8 to 34.3Cochran-Mantel-Haenszel test adjusted for stratum (geographic region).

Adverse events

Collected over From the first dose of study drug up to 30 days after last dose. Period 1: 16 weeks, Period 2: 72 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Placebo0/40 (0%)1/40 (2.5%)15/40 (37.5%)
Period 1: Upadacitinib 7.5 mg0/42 (0%)2/42 (4.8%)21/42 (50%)
Period 1: Upadacitinib 15 mg0/42 (0%)1/42 (2.4%)17/42 (40.5%)
Period 1: Upadacitinib 30 mg0/42 (0%)0/42 (0%)21/42 (50%)
Period 1+2: Upadacitinib 7.5 mg0/42 (0%)2/42 (4.8%)23/42 (54.8%)
Period 1+2: Upadacitinib 15 mg0/42 (0%)1/42 (2.4%)22/42 (52.4%)
Period 1+2: Upadacitinib 30 mg2/114 (1.8%)7/114 (6.1%)68/114 (59.6%)
Period 1+2: Placebo0/93 (0%)1/93 (1.1%)19/93 (20.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 7.5 mgPeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 1+2: Upadacitinib 7.5 mgPeriod 1+2: Upadacitinib 15 mgPeriod 1+2: Upadacitinib 30 mgPeriod 1+2: Placebo
ATRIAL FIBRILLATIONCardiac disorders1/400/420/420/420/420/420/1141/93
APPENDICITISInfections and infestations0/400/421/420/420/421/420/1140/93
PERICORONITISInfections and infestations0/401/420/420/421/420/420/1140/93
SKIN INFECTIONInfections and infestations0/401/420/420/421/420/420/1140/93
DERMATITIS ATOPICSkin and subcutaneous tissue disorders0/401/420/420/421/420/420/1140/93
CARDIO-RESPIRATORY ARRESTCardiac disorders0/400/420/420/420/420/421/1140/93
PERICARDITISCardiac disorders0/400/420/420/420/420/421/1140/93
OESOPHAGEAL FISTULAGastrointestinal disorders0/400/420/420/420/420/421/1140/93
SEPSISInfections and infestations0/400/420/420/420/420/421/1140/93
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/400/420/420/420/420/421/1140/93
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPeriod 1: PlaceboPeriod 1: Upadacitinib 7.5 mgPeriod 1: Upadacitinib 15 mgPeriod 1: Upadacitinib 30 mgPeriod 1+2: Upadacitinib 7.5 mgPeriod 1+2: Upadacitinib 15 mgPeriod 1+2: Upadacitinib 30 mgPeriod 1+2: Placebo
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/407/425/425/427/427/4226/1145/93
DERMATITIS ATOPICSkin and subcutaneous tissue disorders2/405/422/424/426/425/4222/1142/93
ACNESkin and subcutaneous tissue disorders1/404/422/426/424/422/4213/1141/93
NASOPHARYNGITISInfections and infestations1/402/424/423/423/425/4211/1141/93
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations2/400/423/424/420/423/427/1143/93
HEADACHENervous system disorders1/403/423/424/423/423/427/1142/93
HERPES ZOSTERInfections and infestations0/400/420/420/420/420/4210/1140/93
NAUSEAGastrointestinal disorders1/403/421/423/423/421/426/1142/93
INFLUENZAInfections and infestations0/403/420/420/423/420/423/1140/93
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/403/420/420/423/420/420/1140/93

Baseline characteristics

All randomized participants (intent-to-treat population)

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean39.9 ± 17.5241.5 ± 15.3638.5 ± 15.2439.9 ± 15.3039.9 ± 15.77
Age, Customized
Age, Customized(Participants)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 40 years2522252294
40 - 64 years1116141758
≥ 65 years543315
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female1714122063
Male24283022104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino02215
Not Hispanic or Latino41404041162
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
White2824212396
Black or African American6710629
Asian7991338
American Indian/Alaska Native00101
Native Hawaiian or Other Pacific Islander02103
Geographic Region
Geographic Region(Participants)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
US/Canada29292929116
EU/Australia1011101041
Japan223310
Duration of Atopic Dermatitis Diagnosis
Duration of Atopic Dermatitis Diagnosis(years)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean26.84 ± 18.7630.44 ± 18.0722.59 ± 15.7824.24 ± 13.5826.02 ± 16.76
Eczema Area and Severity Index (EASI)
Eczema Area and Severity Index (EASI)(units on a scale)PlaceboUpadacitinib 7.5 mgUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean32.62 ± 14.4931.42 ± 15.7631.40 ± 12.2628.15 ± 11.6230.89 ± 13.61
08

Study locations

34 sites
  • ForCare Clinical Research /ID# 157974
    Tampa, Florida 33613-1244, United States
  • Advanced Medical Research /ID# 154516
    Sandy Springs, Georgia 30328-6141, United States
  • DermAssociates /ID# 153584
    Rockville, Maryland 20850, United States
  • Tufts Medical Center /ID# 153586
    Boston, Massachusetts 02111, United States
  • Psoriasis Treatment Ctr NJ /ID# 153578
    East Windsor, New Jersey 08520, United States
  • Icahn School of Med Mt. Sinai /ID# 153582
    New York, New York 10029, United States
  • Univ Rochester Med Ctr /ID# 154477
    Rochester, New York 14642, United States
  • Arlington Research Center, Inc /ID# 154522
    Arlington, Texas 76011, United States
  • Modern Research Associates, PL /ID# 154487
    Dallas, Texas 75231, United States
  • Center for Clinical Studies /ID# 153589
    Houston, Texas 77004, United States
  • Woden Dermatology /ID# 157907
    Phillip, Australian Capital Territory 2606, Australia
  • St George Hospital /ID# 157908
    Kogarah, New South Wales 2217, Australia
  • Specialist Connect Pty Ltd /ID# 157909
    Woolloongabba, Queensland 4102, Australia
  • Skin Health Institute Inc /ID# 157906
    Carlton, Victoria 3053, Australia
  • Institute for Skin Advancement /ID# 153246
    Calgary, Alberta T3A 2N1, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 153241
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research /ID# 153239
    Surrey, British Columbia V3V 0C6, Canada
  • CCA Medical Research /ID# 155817
    Ajax, Ontario L1S 7K8, Canada
  • Lynderm Research Inc. /ID# 153242
    Markham, Ontario L3P 1X2, Canada
  • Dermatology Ottawa Research Centre /ID# 153248
    Ottawa, Ontario K2C 3N2, Canada
  • K. Papp Clinical Research /ID# 153244
    Waterloo, Ontario N2J 1C4, Canada
  • Mehiläinen Neo /ID# 154960
    Turku, Varsinais-Suomi 20520, Finland
  • Mikkeli Central Hospital /ID# 154959
    Mikkeli, 50100, Finland
  • TFS Trial Form Support GmbH /ID# 155442
    Hamburg, 20354, Germany
  • Fukuoka University Hospital /ID# 152714
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • Takagi Dermatological Clinic /ID# 152706
    Obihiro-shi, Hokkaido 080-0013, Japan
  • Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 153781
    Sapporo-shi, Hokkaido 060-0063, Japan
  • Nippon Medical School Hospital /ID# 153287
    Tokyo, 113-8602, Japan
  • Radboud Universitair Medisch Centrum /ID# 153688
    Nijmegen, Gelderland 6525 GA, Netherlands
  • Academisch Medisch Centrum /ID# 153596
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Universitair Medisch Centrum Groningen /ID# 153595
    Groningen, 9713 GZ, Netherlands
  • Universitair Medisch Centrum Utrecht /ID# 153687
    Utrecht, 3584 CX, Netherlands
  • Hospital Santa Creu i Sant Pau /ID# 153519
    Barcelona, 08026, Spain
  • Hospital Univ Germans Trias I /ID# 155598
    Barcelona, 08916, Spain
09

References and documents

Publications

  • Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, Beck LA, Mohamed MF, Othman AA, Anderson JK, Gu Y, Teixeira HD, Silverberg JI. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 Mar;145(3):877-884. doi: 10.1016/j.jaci.2019.11.025. Epub 2019 Nov 29. PubMed 31786154 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Aug 2017, 9 months.

Results were first posted in Jul 2020, 2 years 11 months after primary completion. A results delay was requested in Aug 2018.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2016
First posted
Oct 5, 2016
StartActual
Oct 25, 2016
Primary completionActual
Aug 10, 2017
CompletionActual
Jan 31, 2019
Results delay requested
Aug 1, 2018
Results first posted
Jul 16, 2020
Last update
Jul 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02925117
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
Oct 25, 2016
Primary completion
Aug 10, 2017
Completion
Jan 31, 2019
Results posted
Jul 16, 2020
Last update
Jul 16, 2020

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion